Literature DB >> 14500384

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

H T Claude Chan1, David Hughes, Ruth R French, Alison L Tutt, Claire A Walshe, Jessica L Teeling, Martin J Glennie, Mark S Cragg.   

Abstract

Rituximab is routinely used for the treatment of neoplasia, although the mechanism of action remains uncertain. In the current study, CD20-induced apoptosis was investigated with a panel of anti-CD20 monoclonal antibodies (mAb) in a wide range of cell lines. A hierarchy of mAb activity was apparent, with the B1 mAb generally the most potent. Apoptosis through CD20 was dependent on the nature of mAb binding and correlated with the extent of homotypic cell adhesion induced. However, using anti-CD20 mAb, which vary in the extent to which they redistribute wild-type and mutant CD20 molecules to membrane rafts, we showed that CD20-induced apoptosis was independent of translocation to TX-100 insoluble rafts. Using crmA-transfected cells and caspase inhibitors, we showed that phosphatidylserine translocation and mitochondrial permeability transition evoked during CD20-induced apoptosis appeared caspase independent. Furthermore, in cytoplasts which lack mitochondria and in Bcl(2)-transfected cells, phosphatidylserine was still translocated to the cell surface after CD20 stimulation. Together, these data imply that CD20 can evoke apoptosis without the involvement of mitochondria and caspases and irrespective of redistribution into TX-100 insoluble membrane rafts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 2.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

Authors:  E Janas; R Priest; J I Wilde; J H White; R Malhotra
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.

Authors:  Tammy L Unruh; Haidong Li; Cathlin M Mutch; Neda Shariat; Lana Grigoriou; Ratna Sanyal; Christopher B Brown; Julie P Deans
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

5.  Regulation of CD20 expression by radiation-induced changes in intracellular redox status.

Authors:  Damodar Gupta; Meredith E Crosby; Alexandru Almasan; Roger M Macklis
Journal:  Free Radic Biol Med       Date:  2007-11-01       Impact factor: 7.376

6.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

7.  Engaging the lysosomal compartment to combat B cell malignancies.

Authors:  Kirsten Grønbaek; Marja Jäättelä
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 9.  Anti-CD20 monoclonal antibodies: historical and future perspectives.

Authors:  Sean H Lim; Stephen A Beers; Ruth R French; Peter W M Johnson; Martin J Glennie; Mark S Cragg
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

10.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Authors:  Laurie H Sehn; Andre Goy; Fritz C Offner; Giovanni Martinelli; M Dolores Caballero; Ole Gadeberg; Tara Baetz; Andrew D Zelenetz; Gianluca Gaidano; Luis E Fayad; Rena Buckstein; Jonathan W Friedberg; Michael Crump; Branimir Jaksic; Pier Luigi Zinzani; Swaminathan Padmanabhan Iyer; Deniz Sahin; Akiko Chai; Günter Fingerle-Rowson; Oliver W Press
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.